Sensoril (Withania somnifera)

Sensoril is a patented, standardized extract of Withania somnifera root and leaf, concentrated to deliver withanolides and withanosides — the primary bioactive compounds that modulate the hypothalamic-pituitary-adrenal (HPA) axis to reduce cortisol and support adaptogenic responses. It is clinically dosed at 125–250 mg daily, distinguishing it from generic ashwagandha extracts by its consistent glycowithanolide content.

Origin & History

Sensoril is a branded, standardized aqueous extract derived from the roots and leaves of Withania somnifera (Ashwagandha), a shrub native to India, the Middle East, and parts of Africa. It is produced using a water-based extraction process without chemical solvents, resulting in a full-spectrum extract standardized to ~10% withanolide glycosides with reduced withaferin A content (<0.5%).

Historical & Cultural Context

Withania somnifera (Ashwagandha) has been used for over 3,000 years in Ayurveda as a rasayana (rejuvenator) for stress, fatigue, vitality, and reproductive health. Traditional preparations included root powder or decoctions for insomnia and anxiety, while leaves were used for swellings and fever.

Health Benefits

• Significantly increases muscle strength and size in resistance-trained individuals (Strong evidence: 12-week RCT showed 138% strength increase vs 80% placebo) • Reduces exercise-induced muscle damage markers including creatine kinase (Strong evidence: controlled trial in 60 men) • Modulates stress response through HPA axis regulation and cortisol reduction (Moderate evidence: general ashwagandha studies show cortisol drops, Sensoril-specific data limited) • May enhance cognitive function through acetylcholine modulation and BDNF upregulation (Preliminary evidence: small pilots <50 participants) • Supports GABAergic activity for potential anxiolytic effects (Preliminary evidence: mechanism studies, limited Sensoril-specific clinical data)

How It Works

Sensoril's withanolides suppress nuclear factor-kappa B (NF-κB) signaling, reducing pro-inflammatory cytokine production including TNF-α and IL-6, which contributes to its muscle recovery effects. The extract also inhibits the enzyme 11β-hydroxysteroid dehydrogenase and modulates glucocorticoid receptor sensitivity, blunting excessive cortisol output from the HPA axis under chronic stress. Additionally, withanosides promote BDNF expression and may enhance GABAergic neurotransmission, partially explaining observed reductions in anxiety and improvements in sleep quality.

Scientific Research

A key randomized, double-blind, placebo-controlled trial (n=60 resistance-trained men) tested 500 mg/day Sensoril for 12 weeks, demonstrating significant improvements in muscle strength and size (PMC6266766). While general Withania somnifera extracts have robust evidence for stress reduction (PMID: 23439798), Sensoril-specific trials remain limited to the strength study and smaller cognitive/sleep pilots.

Clinical Summary

A 12-week randomized controlled trial in resistance-trained men demonstrated a 138% increase in muscle strength in the Sensoril group versus 80% in placebo, with statistically significant reductions in creatine kinase, a biomarker of exercise-induced muscle damage, in a separate controlled trial involving 60 men. Cortisol reduction of approximately 14–32% has been documented in placebo-controlled trials using 125–250 mg doses, making it one of the more potent standardized ashwagandha extracts by weight. Evidence for cognitive benefits and sleep quality is preliminary but supported by small-to-medium RCTs. Overall, the evidence base is stronger than most adaptogen extracts but is limited by relatively small sample sizes and short trial durations.

Nutritional Profile

Sensoril is a patented, standardized extract of Withania somnifera (ashwagandha) root and leaf, standardized to contain a minimum of 10% withanolide glycosides (withanolides A, B, and related steroidal lactones), 32% oligosaccharides, and less than 0.5% withaferine A (a potentially cytotoxic withanolide minimized in this extract compared to KSM-66). Key bioactive compounds include: withanolide glycosides (~10% by weight), withaferin A (<0.5%), withanosides (sitoindosides VII and VIII), and alkaloids including isopelletierine and anaferine at trace levels. Oligosaccharides comprise approximately 32% of the extract and are believed to contribute to adaptogenic and immunomodulatory effects. The extract contains negligible macronutrients at typical supplemental doses (125–500 mg/day): protein <0.1 g, carbohydrates <0.2 g, fat <0.05 g, calories <2 kcal per dose. Micronutrient content at supplemental doses is not nutritionally significant. Iron is present in whole ashwagandha root at approximately 3.3 mg/100g dry weight, but at extract doses this is negligible. Bioavailability: withanolide glycosides demonstrate improved oral bioavailability compared to free withanolides due to glycosylation enhancing aqueous solubility; peak plasma concentrations typically reached within 2–3 hours post-ingestion. The leaf-and-root combination in Sensoril provides a distinct withanolide profile compared to root-only extracts, with higher withanosides relative to withaferine A, which is associated with a more favorable safety profile.

Preparation & Dosage

Clinically studied dosage: 500 mg/day Sensoril (divided doses) for strength and recovery benefits over 12 weeks. General ashwagandha root extracts use 300-600 mg/day for stress/cognition benefits. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Piperine, Rhodiola rosea, L-theanine, Magnesium glycinate, Vitamin D3

Safety & Interactions

Sensoril is generally well tolerated at 125–250 mg daily, with the most commonly reported side effects being mild gastrointestinal upset, loose stools, and drowsiness, particularly at higher doses. It may potentiate sedative medications including benzodiazepines, barbiturates, and sleep aids due to its GABAergic activity, and individuals on thyroid hormone medications should exercise caution as ashwagandha can stimulate thyroid hormone synthesis. Sensoril is contraindicated during pregnancy due to potential uterotonic effects observed in animal models, and individuals with autoimmune conditions such as Hashimoto's thyroiditis, lupus, or rheumatoid arthritis should consult a physician before use. No serious adverse events have been reported in clinical trials at standard doses, and it carries GRAS (Generally Recognized As Safe) status in the United States.